Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | ACR | P10323 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775653 | 0.91 | L3MBTL1 (0.47) | L3MBTL1MAPTACRHSP90AA1HSP90AB1 | |
| SCHEMBL21047410 | 0.91 | L3MBTL1 (0.47) | L3MBTL1MAPTACRHSP90AA1HSP90AB1 | |
| SCHEMBL26690705 | 0.86 | ALDH1A1 (0.42) | L3MBTL1MAPTACRHSP90AA1HSP90AB1 | |
| SCHEMBL29775738 | 0.85 | L3MBTL1 (0.53) | L3MBTL1MAPTACRTP53ALDH1A1 | |
| SCHEMBL16111931 | 0.85 | L3MBTL1 (0.53) | L3MBTL1MAPTACRTP53ALDH1A1 | |
| SCHEMBL1544635 | 0.84 | L3MBTL1 (0.54) | L3MBTL1MAPTACRTP53ALDH1A1 | |
| SCHEMBL29775892 | 0.82 | ACKR3 (0.49) | L3MBTL1MAPTACRTP53ALDH1A1 | |
| SCHEMBL2032412 | 0.82 | ACKR3 (0.49) | L3MBTL1MAPTACRTP53ALDH1A1 | |
| SCHEMBL21523795 | 0.81 | MAPT (0.51) | L3MBTL1MAPTACRTP53ALDH1A1 | |
| SCHEMBL14239264 | 0.80 | MAPT (0.43) | L3MBTL1MAPTACRHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340546-A1 | HSD17B13 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-11-06 | — | — | US | disclosed |
| CN-119317627-A | HSD17B13 inhibitors | 勃林格殷格翰国际有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023237504-A1 | HSD17B13 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237504-A1 | HSD17B13 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340546-A1 | HSD17B13 INHIBITORS | HSD17B3, HSD17B13, HSD17B1 | L3MBTL1 3702/4885MAPT 4194/4885ACR 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.